Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
17.74
+0.28 (1.60%)
At close: Sep 26, 2024, 4:00 PM
17.75
+0.01 (0.06%)
After-hours: Sep 26, 2024, 5:05 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 18.75, with a low estimate of 11 and a high estimate of 26. The average target predicts an increase of 5.69% from the current stock price of 17.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $24 → $26 | Strong Buy | Maintains | $24 → $26 | +46.56% | Sep 3, 2024 |
| Barclays | Barclays | Buy Maintains $21 → $22 | Buy | Maintains | $21 → $22 | +24.01% | Aug 1, 2024 |
| UBS | UBS | Strong Buy Maintains $22 → $24 | Strong Buy | Maintains | $22 → $24 | +35.29% | Jul 10, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $19 → $23 | Strong Buy | Maintains | $19 → $23 | +29.65% | Jun 27, 2024 |
| Barclays | Barclays | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +18.38% | Jun 5, 2024 |
Financial Forecast
Revenue This Year
16.58B
from 15.85B
Increased by 4.60%
Revenue Next Year
17.13B
from 16.58B
Increased by 3.32%
EPS This Year
2.48
from -0.50
EPS Next Year
2.81
from 2.48
Increased by 13.63%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 17.1B | 18.2B | 19.2B |
| Avg | 16.6B | 17.1B | 17.5B |
| Low | 15.9B | 16.0B | 16.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 8.2% | 9.6% | 12.3% |
| Avg | 4.6% | 3.3% | 2.2% |
| Low | 0.1% | -3.7% | -5.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.58 | 3.13 | 3.16 |
| Avg | 2.48 | 2.81 | 2.97 |
| Low | 2.32 | 2.61 | 2.73 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 26.4% | 12.4% |
| Avg | - | 13.6% | 5.4% |
| Low | - | 5.3% | -2.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.